Binding Letter of Intent to replace existing $53m facility
Filed with ASX · · 3 pages · English
Nexalis Therapeutics Limited on 6ix
In the deck
Earlier from Nexalis Therapeutics
- Suspension from Quotation
- Mar26 Appendix 4C Cash Flow Report
- Significant Milestone - First Patient Screened IRX-211 Ph2
- First patient dosed in IRX-616a Phase 1 trial
- First eligible participant screened - phase 1 IRX-616a study
Later from Nexalis Therapeutics
- Update on Funding Facility and Clinical Program
- Jun26 Appendix 4C Cash Flow Report
- Removal of draft wording in the directors report HY accounts
- Sep26 Quarterly Activities Report
- Sep26 Appendix 4C Cash Flow Report
Follow Nexalis Therapeutics into a list and get an email when it puts out news.
Follow Nexalis Therapeutics